Posttransplant Cyclophosphamide Effective in Graft Vs Host Disease Prophylaxis
Researchers sought to determine whether posttransplant cyclophosphamide would be effective in GVHD prophylaxis for patients who underwent mismatched unrelated donor HCT.
Diagnosis & Disease Information
Rezurock Approved for Chronic Graft-vs-Host Disease
The approval was based on data from a phase 2 trial that evaluated Rezurock in 65 patients with chronic GVHD who received 2 to 5 prior lines of systemic therapy.
Belumosudil Yields Clinically Meaningful Outcomes in Patients With Chronic Graft-Vs-Host Disease
Researchers sough to determine whether belumosudil would help treat patients with chronic GVHD.
Anti-T Cell Lymphocyte Globulin Shows Similar Long-Term Outcomes to Post-Transplant Cyclophosphamide for GVHD Prophylaxis
Researchers sought to determine if GVHD prophylaxis with ATLG would be the same as PTCy in terms of long-term outcomes.
BAFF May Be Promising Therapeutic Target in Graft-Vs-Host Disease
Researchers sought to determine whether targeting BAFF and BCR pathways may improve outcomes in patients with chronic GVHD risk.
Low-Dose Anti-Thymoglobulin May Help Prophylaxis for Graft Vs Host Disease
Researchers sought to determine whether adding ATG would help improve prophylaxis for GVHD in patients with lymphoid malignancies.
Knowledge of Human Leukocyte Antigen Loss After Haploidentical Transplantation Helps Manage Patients With Hematologic Malignancies
Researchers sought to determine whether detecting HLA loss would be helpful in managing patients with hematologic malignancies who relapsed after haploidentical transplantation.
Risk Factors for Graft Rejection and Pediatric Hematopoietic Stem Cell Transplantation
Researchers sought to determine risk factors for graft rejection in pediatric patients receiving hematopoietic stem cell transplantation for bone marrow failure.
Alemtuzumab as Part of Conditioning Therapy for Graft-Vs-Host Disease in Children and Young Adults
Researchers sought to determine whether conditioning chemotherapy containing alemtuzumab may improve outcomes for GVHD in pediatric patients with hematologic malignancies.
AlloHCT Following Treatment With PD-1 mAbs Beneficial in Classic Hodgkin Lymphoma
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
- Loading...
Loading...
Loading... 
Loading...